Poxel SA, a biopharmaceutical company dedicated to novel treatments for type 2 diabetes, recently announced in a press release that its presentation at the 6th World Congress on Targeting Mitochondria in Berlin, Germany, Oct. 28–30, 2015, entitled “Imeglimin, a New Mitochondria Targeted Agent for Type 2 Diabetes Treatment,” has been selected as the Best Short Oral Communication at the Congress.
The World Congress on Targeting Mitochondria covers a range of novel approaches, pioneering strategies, and clinical applications in the mitochondrial field and is organized by the World Mitochondria Society (WMS).
Imeglimin is an oral therapeutic agent for diabetes that acts by targeting the mitochondrial dysfunction associated with the disease. In the presentation, Poxel showed the unique mitochondria-targeting mechanism of action of Imeglimin, which ultimately results in an increase of both glucose-dependent insulin secretion and sensitivity.
“We are truly honored and thankful to the WMS Scientific Committee for this award that recognizes the quality of our work and the innovative mechanism of action of our drug candidate, Imeglimin, a new antidiabetic agent, targeting the mitochondria for the management of type 2 diabetes,” said Dr. Sebastien Bolze, EVP Non-Clinical Development and CSO of Poxel, in the release.
“Each year, the WMS recognizes a company which has made significant contributions to translating their research into real applications for the management and prevention of disease progression,” explained Dr. Marvin Edeas, Professor and Chairman of the WMS. “As chairman of the scientific committee, I was highly intrigued by the study presented by Dr. Bolze. He clearly outlined how this new drug can modulate mitochondria function and how these effects can affect insulin sensitivity and secretion. Additionally, the effects on oxidative stress reduction and cell protection were also highlighted.”
Imeglimin was shown to target two important features linked to mitochondrial bioenergetics: the mitochondrial respiratory chain and the mitochondrial permeability transition pore (mPTP). Its action ultimately leads to a reduction in glycemic parameters and a delay in disease progression.
Mitochondrial Disease News has previously written about the presentation of Imeglimin’s preclinical data at the 6th World Congress on Targeting Mitochondria. To know more about it, including Imeglimin’s mechanism of action, please follow this link.